Drug intelligence / Profile preview

valsartan + amlodipine + chlorthalidone

Development stage
Phase 3
Lead developer
AJU Pharm
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a **fixed-dose combination** of three antihypertensive agents: valsartan, amlodipine, and chlorthalidone. - **Valsartan** is an angiotensin II receptor blocker (ARB) that inhibits the action of angiotensin II on the AT1 receptor, leading to vasodilation and reduced blood pressure. - **Amlodipine** is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing arterial vasodilation and reduction in blood pressure. - **Chlorthalidone** is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule of the nephron, promoting diuresis and reducing blood volume and blood pressure. This triple combination is typically used for the treatment of **hypertension**, especially in patients who require multiple antihypertensive agents to achieve target blood pressure levels. Most commonly, fixed combinations available in the market substitute chlorthalidone with hydrochlorothiazide in similar triple therapies, but the pharmacologic effects are considered clinically similar.

Other names
valsartan + amlodipine + chlorthalidone
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on valsartan + amlodipine + chlorthalidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valsartan + amlodipine + chlorthalidone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call